ABVC — ABVC Biopharma Share Price
0.000.00%
Last trade - 00:00- $50.99m
- $54.96m
- $0.51m
- 39
- 11
- 85
- 41
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 9.44 | ||
| Price to Tang. Book | 9.44 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 100.3 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -20.85% | ||
| Return on Equity | -27.46% | ||
| Operating Margin | -334.05% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.48 | 0.36 | 0.97 | 0.15 | 0.51 | 4.17 | 35.28 | -6.2% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing products and technologies to combat various diseases. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV- 1501, ABV-1519 and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine to treat Major Depressive Disorder (MDD). ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. It also focuses on the development of new drugs and medical devices derived from plants.
Directors
- Eugene Jiang CHM (34)
- Howard Doong CEO (63)
- Chihliang An CFO (40)
- Chi-Hsin King CSO (71)
- Chang-Jen Jiang DRC (65)
- Tsang-Ming Jiang DRC (60)
- Tsung-Shann Jiang DRC (67)
- Hwalin Lee DRC (84)
- Yen-Hsin Chou IND (32)
- Shin-Yu Miao IND (57)
- Yoshinobu Odaira IND (72)
- Norimi Sakamoto IND (50)
- Shih-Chen Tzeng IND (63)
- Ming-Fong Wu IND (45)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- February 6th, 2002
- Public Since
- November 9th, 2004
- No. of Shareholders
- 656
- No. of Employees
- 16
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 23,541,824
- Address
- 44370 Old Warm Springs Blvd, FREMONT, 94538-6148
- Web
- https://abvcpharma.com/
- Phone
- +1 5106680881
- Auditors
- Simon & Edward LLP
Upcoming Events for ABVC
Similar to ABVC
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
Addex Therapeutics
NASDAQ Capital Market
FAQ
What is the ABVC Biopharma share price?
As of Today at 10:02 UTC, shares in ABVC Biopharma are trading at $3.04. This share price information is delayed by 15 minutes.
How has the ABVC Biopharma share price performed this year?
Shares in ABVC Biopharma last closed at $3.04 and the price had moved by +305.39% over the past 365 days. In terms of relative price strength the ABVC Biopharma share price has outperformed the S&P500 Index by +247.4% over the past year.
What are the analyst and broker recommendations for ABVC Biopharma?
The overall consensus recommendation for ABVC Biopharma is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the ABVC Biopharma dividend yield?
ABVC Biopharma does not currently pay a dividend.
Does ABVC Biopharma pay a dividend?
ABVC Biopharma does not currently pay a dividend.
When does ABVC Biopharma next pay dividends?
ABVC Biopharma does not currently pay a dividend.
How do I buy ABVC Biopharma shares?
To buy shares in ABVC Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of ABVC Biopharma?
As of the previous close price of $3.04, shares in ABVC Biopharma had a market capitalisation of $50.99m.
Where are ABVC Biopharma shares listed?
Here are the trading details for ABVC Biopharma:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ABVC
What kind of share is ABVC Biopharma?
Based on an overall assessment of its quality, value and momentum ABVC Biopharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a ABVC Biopharma share price forecast for 2025?
The analyst consensus target price for shares in ABVC Biopharma is $2.02. That is 33.55% below the last closing price of $3.04.
Analysts covering ABVC Biopharma currently have a consensus Earnings Per Share (EPS) forecast of -$0.46 for the next financial year.
Find out moreWhat is the trend in the ABVC Biopharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ABVC Biopharma. Over the past six months, its share price has outperformed the S&P500 Index by +531.04%.
As of the last closing price of $3.04, shares in ABVC Biopharma were trading +143.86% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the ABVC Biopharma PE Ratio?
The ABVC Biopharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.04.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of ABVC Biopharma?
ABVC Biopharma's management team is headed by:
- Eugene Jiang - CHM
- Howard Doong - CEO
- Chihliang An - CFO
- Chi-Hsin King - CSO
- Chang-Jen Jiang - DRC
- Tsang-Ming Jiang - DRC
- Tsung-Shann Jiang - DRC
- Hwalin Lee - DRC
- Yen-Hsin Chou - IND
- Shin-Yu Miao - IND
- Yoshinobu Odaira - IND
- Norimi Sakamoto - IND
- Shih-Chen Tzeng - IND
- Ming-Fong Wu - IND